Ok so I want to start off with a few things before I get
Ok so I want to start off with a few things before I get into the interview. I would like to start off by commending Ziv. He was willing to meet with me at 8am (even though they start work significantly later to mirror American hours) and he allotted essentially an infinite amount of time for me. I want to follow up with an apology to you guys. I had to catch a flight and this was very last minute so I only had about half an hour with him. I didn't get to get as deep into it as I would like or get to ask all the questions submitted. That being said I will detail the brief interview below. There will be some places where I insert my opinion and I will make those points clear.
First and foremost the office definitely exists guys haha. It's a standard office with a beautiful lobby in a mini office park. The outside looks average but inside it looks modern. I took a few pictures and am on my phone now. Maybe I can post them from my computer later? I also passed by tel hashomer hospital. I have asked many people there about it and it's reputation is outstanding.
Now on to the interview
Q: what other uses are being tested for the cream? I believe I heard something about basal cell carcinoma
A: I can't get into those details but I can tell you basal cell carcinoma is not something we are testing now. It is definitely on our radar for the near future
Q: does the cream have any side effects? What makes it different from other products?
A: no there are no side effects which is a benefit of this cream unlike other medications. Also our product is natural and does not have chemicals in it like other treatments. Furthermore I believe our product will be the only psoriasis cream clinically tested on the market. If you can find another cream that was let me know (this is Ziv btw)
Q: what country do you plan to market to first?
A: US but we are also excited to take advantage of the European market. It's huge and often gets overlooked.
Q: so you want to enter the US market. This is through Medmar correct? Is this the same one in Illinois?
A: yes we will distribute through Medmar. No it's not the same company in Illinois.
Q: consulting contracts. When do you expect to generate revenue from them
A: sometime this year
Q: any myeloma updates?
A: not that I can say
Q: well are you more advanced then the previous article about killing 100% in 60% of myeloma cells in tested animals?
A: yes we are more advanced than that. I can't comment on specifics unfortunately. I don't want to tip off competition.
Q: how many patents do you have. Are they all provisional? Are they all protected by USPTO?
A: 8 provisional and they are all protected by USPTO. We filled the provisional with the intention of working our way to a real patent. It's a process. We also filled a PCT patent on five of them which extends our ownership of idea and time period for 18 months as we flush out these concepts further. But yes these are currently protected.
Q: is the condom one of those
A: of course it could be a fun way to take/give medication
Q: what other diseases are currently in the pipeline?
A: I cannot mention anything that wasn't published but there are others
Q: who do you see as your biggest competitor?
A: no competition at the moment. There are so many possibilities for cannabis and medical application that there isn't any reason for people to step on each other's toes. The more people who embrace cannabis the more beneficial it is for the industry.
Q: will you touch the raw plant or just oils
A: just oils for now
Q: are the rumors about Teva trying to buy you out true?
A: they called us and wanted to sign an NDA to have access to our information. There was no reason for us to give them access to our intellectual property/information so we denied their request.
Q: why did you go public?
A: three years ago cannabis was not taken seriously. When I told my mother what I was doing she thought I was a drug dealer and wanted nothing to do with it. Others had a similar reaction At the time buying the ticker was the only way to raise funds. If I could have raised the money at the time I would have preferred to be private. (MY OPINION: now cannabis is more widely accepted I think their recent partnerships and agreements point to this. Their non dilutive financing points to their current goals not to just keep issuing shares. I also think this rarity is why we have found such a gem and ground floor opportunity. Had cannabis been widelt accepted in 2014 I don't think theyd be public right now )
Me: well I'm glad you went public haha
He then let me see the cream. While I don't have psoriasis I can say the cream didn't have any noticable negative effects on my skin. Cream is kind of thick and you can smell the weed haha but the smell subsidies after rubbing it on.
MY OPINION: while he didn't say it, from my own interpretations of body language and context clues, I believe efficacy is a given. It almost seemed as if it was assumed that it was coming to market throughout our convo Once again this is my opinion not fact.
Also MY OPINION from talking to him he is aware of the fluctuations in the stock price but doesn't seem concerned. I get the impression he believes long term everything will work itself out.
Overall he was very nice and willing to answer all my questions. I know there are quite a few topics that might have benefitted from a deeper dive but do to my own time restrictions I couldn't get to those. I hope at least one of these answers helps y'all in your DD
22
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Rising Medical's Continued Ascent In a world where the list of high-performing companies is as long as a trader's bad day, Rising Medical Solutions, out of Chicago, has snagged its ninth appearance on the Inc. 5000 list. This isn’t just any roll call; we're talking about a spotlight for America’s fastest-growing private companies—a badge of honor for business...
Continue Reading
Atlas-SSI Makes Waves with Linita Acquisition Here's the kind of news that makes an old market hound sit up and take notice. Atlas-SSI, the big cheese in North America for water management solutions, has gone and snagged Linita Design & Manufacturing. Why's this worth talking about? Linita isn't just any player—they've been crafting custom-engineered hydro-mechanical...
Continue Reading
GreenCore's Bold Move in FMCG Retail Just when you thought retail couldn't get any more futuristic, here comes GreenCore Solutions Corp. (GSC) shaking up the game with their Agentic Shopping Hub. For the uninitiated, we're not just talking about another e-commerce gimmick—this is a cultural shift. FMCG brands are being told to 'bring their agent' into a realm where AI...
Continue Reading
Challenging Market Yet Strategic Steps Talk about a seesaw of a quarter for JELD-WEN, folks. On the one hand, their net revenues took a dip to $798.5 million, shaving off 1.4% from last year. If you ask why, blame it on a 2% slide in volume/mix. That uptick in price? Well, 1% wasn't enough to save the day. "Our third-quarter results reflect the continued progress we are...
Continue Reading
Diving Into Quantum Cryptography for Blockchain Instanodes is throwing down the gauntlet for the blockchain crowd as the field of quantum computing edges ever closer to unsettling the cryptographic order. This company's latest play? Post-quantum account engineering for major players like Ethereum and Solana. And it's not just tinkering—they're giving the status quo a...
Continue Reading
Doximity Lands in Hot Water: The Stakes for Investors Alright, traders, there's a storm brewing around Doximity (NYSE:DOCS), and it's a doozy. A class action lawsuit has been slapped on this digital platform for medical pros, and the accusations are serious. If you rode the wave and snagged yourself some shares between August 8, 2024, and May 13, 2026, you're right in the...
Continue Reading
Election Day Drama: Metals Market Jitters You'd think with all the election day hoopla, the metal futures would hold steady. But here we are, seeing gold, silver, and copper futures retracting like a scared turtle. Monday, they all roared upward. Tuesday morning, they're backpedaling. December gold futures took a hit, dropping 0.78% to land at $3,938.50 an ounce. Silver...
Continue Reading
Zuellig Pharma's Strategic Leap in Hangzhou You know, in the ever-evolving world of biotech and pharmaceuticals, setting up shop in the right locale can mean the difference between breakthroughs and breakdowns. So Zuellig Pharma—a major player, but not exactly a household ticker—made a smart move acquiring a clinical facility in Hangzhou. This is no minor shuffle;...
Continue Reading
Troubles Mount for Qfin Holdings Well, you don't need a crystal ball to see this storm brewing for Qfin Holdings, Inc. (NASDAQ:QFIN). On the heels of a nasty 18.91% nosedive in their stock price, a class action lawsuit is looming overhead like a mischievous cloud ready to rain on investors' parades. It's the kind of legal and financial brew that could leave shareholders...
Continue Reading
Rethinking How Research Data Drives Discovery When researchers generate truckloads of data, finding patterns that lead to breakthroughs often becomes a game of hide and seek. It's like having a jumbo puzzle with pieces scattered all over the place. Enter the NIH Common Fund Data Ecosystem—a game changer attempting to glue together these pieces across the research...
Continue Reading
Top 5 Most Recently Viewed Articles
Swisslog and Medline Enhance Supply Chain with Automation Solution Swisslog, a recognized leader in logistics automation, has embarked on an exciting new project with Medline, a long-standing partner. This collaboration focuses on the implementation of an advanced AutoStore system designed to significantly enhance Medline's order fulfillment capabilities. The New...
Continue Reading
Revolutionizing Healthcare with Wearable Electronic Records In an exciting advancement for digital health, Retrieve Medical Holdings, Inc. (OTC Pink: RMHI) has announced a groundbreaking partnership with MyID, a leader in wearable medical identification technology. This joint venture aims to introduce the first-ever device that integrates a user’s complete, verified...
Continue Reading
Therap Integrates with EVV Aggregator for Enhanced Care Therap Services, a leader in HIPAA-compliant electronic documentation solutions, is taking significant strides forward in support of care providers. By integrating with a new Electronic Visit Verification (EVV) aggregator, Therap aims to enhance the services provided to patients receiving Medicaid personal care and...
Continue Reading
Jabil's stock saw some serious action back in 2024 when BofA Securities hiked its price target from $135 to $150 after a strong Q4 earnings report. They slapped a Buy rating on it, and you know how that goes—traders perk up when the analysts start buzzing about positive outlooks. For fiscal year 2025, Jabil was predicting revenues of around $27 billion and an EPS of...
Continue Reading
AdTech Holding Achieves Recognition for Workplace Excellence AdTech Holding has recently earned the esteemed Great Place To Work® Certification™ for the third consecutive year. This notable achievement reflects the genuine feedback from employees concerning the workplace culture, trust, and the opportunities for professional growth that the company fosters. A...
Continue Reading